Participants
schizophrenia
DISEASE
A total of 66 dyads composed of individuals living with schizophrenia and their caregivers were included in the study. The study was powered for the primary aim of the clinical trial, which was to assess intervention efficacy, and not for the APIM analysis. All treatment-engaged patient participants had an ICD-10 (International Classification of Disease) diagnosis of either schizophrenia (F20, 